Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
- PMID: 16150517
- DOI: 10.1016/j.vaccine.2005.08.048
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
Abstract
T-cell-mediated responses against the liver-stage of Plasmodium falciparum are critical for protection in the human irradiated sporozoite model and several animal models. Heterologous prime-boost approaches, employing plasmid DNA and viral vector delivery of malarial DNA sequences, have proved particularly promising for maximising T-cell-mediated protection in animal models. The T-cell responses induced by this prime-boost regime, in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of "synergistic" prime-boost immunisation. The insert in our first generation clinical constructs is known as multiple epitope-thrombospondin-related adhesion protein (ME-TRAP). We have performed an extensive series of phase I/II trials evaluating various prime-boost combination regimens for delivery of ME-TRAP in over 500 malaria-naïve and malaria-exposed individuals. The three delivery vectors are DNA, modified vaccinia virus Ankara (MVA) and, more recently, fowlpox strain 9 (FP9). Administration was intra-epidermal and intramuscular for DNA and intradermal for MVA and FP9. Doses of DNA ranged from 4 microg to 2mg. Doses of MVA were up to 1.5 x 10(8) plaque forming units (pfu) and of FP9, up to 1.0 x 10(8)pfu. Further trials employing bacille Calmette-Guérin (BCG) as the priming agent and MVA expressing antigen 85A of Mycobacterium tuberculosis as the boosting agent has extended the scope of synergistic prime-boost vaccination. In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials.
Similar articles
-
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24. J Infect Dis. 2004. PMID: 15181568 Clinical Trial.
-
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.Vaccine. 2006 Apr 5;24(15):3026-34. doi: 10.1016/j.vaccine.2005.10.058. Epub 2006 Feb 2. Vaccine. 2006. PMID: 16488059 Clinical Trial.
-
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.PLoS Med. 2019 Apr 30;16(4):e1002790. doi: 10.1371/journal.pmed.1002790. eCollection 2019 Apr. PLoS Med. 2019. PMID: 31039172 Free PMC article. Clinical Trial.
-
Progress in DNA-based heterologous prime-boost immunization strategies for malaria.Immunol Rev. 2004 Jun;199:126-43. doi: 10.1111/j.0105-2896.2004.00138.x. Immunol Rev. 2004. PMID: 15233731 Review.
-
DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.Dev Biol (Basel). 2000;104:171-9. Dev Biol (Basel). 2000. PMID: 11713817 Review.
Cited by
-
Immunogenicity of poxvirus-based vaccines against Nipah virus.Sci Rep. 2023 Jul 14;13(1):11384. doi: 10.1038/s41598-023-38010-2. Sci Rep. 2023. PMID: 37452062 Free PMC article.
-
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial.Lancet Microbe. 2022 Jan;3(1):e11-e20. doi: 10.1016/S2666-5247(21)00193-2. Epub 2021 Nov 3. Lancet Microbe. 2022. PMID: 34751259 Free PMC article. Clinical Trial.
-
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.Int J Hematol. 2021 Nov;114(5):544-553. doi: 10.1007/s12185-021-03215-6. Epub 2021 Sep 24. Int J Hematol. 2021. PMID: 34561840 Free PMC article. Review.
-
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035. doi: 10.1007/s00253-019-09694-2. Epub 2019 Feb 23. Appl Microbiol Biotechnol. 2019. PMID: 30796494 Free PMC article.
-
Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.Hum Vaccin Immunother. 2019;15(1):203-209. doi: 10.1080/21645515.2018.1513439. Epub 2018 Sep 6. Hum Vaccin Immunother. 2019. PMID: 30148692 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical